Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Harrigan

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Nature|October 21, 2011
The evolution of gene expression levels in mammalian organsDavid Brawand, Magali Soumillon, Anamaria Necsulea, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 14, 2019
The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trialDaniel K Burns, Carl Chiang, Kathleen A Welsh-Bohmer, et al.
The Lancet. Neurology|June 19, 2021
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trialDaniel K Burns, Robert C Alexander, Kathleen A Welsh-Bohmer, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Nature|October 21, 2011
The evolution of gene expression levels in mammalian organsDavid Brawand, Magali Soumillon, Anamaria Necsulea, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 14, 2019
The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trialDaniel K Burns, Carl Chiang, Kathleen A Welsh-Bohmer, et al.
The Lancet. Neurology|June 19, 2021
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trialDaniel K Burns, Robert C Alexander, Kathleen A Welsh-Bohmer, et al.
Pageof 2